Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone. 2009

Claire Leroy, and Véronique Bragulat, and Ivan Berlin, and Marie-Claude Grégoire, and Michel Bottlaender, and Dimitri Roumenov, and Frédéric Dollé, and Sandrine Bourgeois, and Jani Penttilä, and Eric Artiges, and Jean-Luc Martinot, and Christian Trichard
INSERM U797, Research Unit Neuroimaging and Psychiatry, Orsay, France. claire.leroy@cea.fr

The inhibition of cerebral monoamine oxidases (MAOs) by cigarette smoke components could participate to the tobacco addiction. However, the actual extent of this inhibition in vivo in smokers is still poorly known. We investigated cerebral MAO-A availability in 7 tobacco-dependent subjects and 6 healthy nonsmokers, using positron emission tomography (PET) and the MAO-A selective radioligand [C]befloxatone. In comparison to nonsmokers, smokers showed a significant overall reduction of [C]befloxatone binding potential (BP) in cortical areas (average reduction, -60%) and a similar trend in caudate and thalamus (-40%). Our findings confirm a widespread inhibition of cerebral MAO-A in smokers. This mechanism may contribute to tobacco addiction and for a possible mood-modulating effect of tobacco.

UI MeSH Term Description Entries
D008297 Male Males
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D010080 Oxazoles Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions. Oxazole,1,3-Oxazolium-5-Oxides,Munchnones,1,3 Oxazolium 5 Oxides
D002250 Carbon Radioisotopes Unstable isotopes of carbon that decay or disintegrate emitting radiation. C atoms with atomic weights 10, 11, and 14-16 are radioactive carbon isotopes. Radioisotopes, Carbon
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012907 Smoking Willful or deliberate act of inhaling and exhaling SMOKE from burning substances or agents held by hand. Smoking Behaviors,Smoking Habit,Behavior, Smoking,Behaviors, Smoking,Habit, Smoking,Habits, Smoking,Smoking Behavior,Smoking Habits

Related Publications

Claire Leroy, and Véronique Bragulat, and Ivan Berlin, and Marie-Claude Grégoire, and Michel Bottlaender, and Dimitri Roumenov, and Frédéric Dollé, and Sandrine Bourgeois, and Jani Penttilä, and Eric Artiges, and Jean-Luc Martinot, and Christian Trichard
May 2003, The Journal of pharmacology and experimental therapeutics,
Claire Leroy, and Véronique Bragulat, and Ivan Berlin, and Marie-Claude Grégoire, and Michel Bottlaender, and Dimitri Roumenov, and Frédéric Dollé, and Sandrine Bourgeois, and Jani Penttilä, and Eric Artiges, and Jean-Luc Martinot, and Christian Trichard
July 2005, The Journal of pharmacology and experimental therapeutics,
Claire Leroy, and Véronique Bragulat, and Ivan Berlin, and Marie-Claude Grégoire, and Michel Bottlaender, and Dimitri Roumenov, and Frédéric Dollé, and Sandrine Bourgeois, and Jani Penttilä, and Eric Artiges, and Jean-Luc Martinot, and Christian Trichard
December 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,
Claire Leroy, and Véronique Bragulat, and Ivan Berlin, and Marie-Claude Grégoire, and Michel Bottlaender, and Dimitri Roumenov, and Frédéric Dollé, and Sandrine Bourgeois, and Jani Penttilä, and Eric Artiges, and Jean-Luc Martinot, and Christian Trichard
November 2013, EJNMMI research,
Claire Leroy, and Véronique Bragulat, and Ivan Berlin, and Marie-Claude Grégoire, and Michel Bottlaender, and Dimitri Roumenov, and Frédéric Dollé, and Sandrine Bourgeois, and Jani Penttilä, and Eric Artiges, and Jean-Luc Martinot, and Christian Trichard
December 2014, Nuclear medicine communications,
Claire Leroy, and Véronique Bragulat, and Ivan Berlin, and Marie-Claude Grégoire, and Michel Bottlaender, and Dimitri Roumenov, and Frédéric Dollé, and Sandrine Bourgeois, and Jani Penttilä, and Eric Artiges, and Jean-Luc Martinot, and Christian Trichard
November 1996, Proceedings of the National Academy of Sciences of the United States of America,
Claire Leroy, and Véronique Bragulat, and Ivan Berlin, and Marie-Claude Grégoire, and Michel Bottlaender, and Dimitri Roumenov, and Frédéric Dollé, and Sandrine Bourgeois, and Jani Penttilä, and Eric Artiges, and Jean-Luc Martinot, and Christian Trichard
May 1985, Psychological medicine,
Claire Leroy, and Véronique Bragulat, and Ivan Berlin, and Marie-Claude Grégoire, and Michel Bottlaender, and Dimitri Roumenov, and Frédéric Dollé, and Sandrine Bourgeois, and Jani Penttilä, and Eric Artiges, and Jean-Luc Martinot, and Christian Trichard
January 2022, Frontiers in neuroscience,
Claire Leroy, and Véronique Bragulat, and Ivan Berlin, and Marie-Claude Grégoire, and Michel Bottlaender, and Dimitri Roumenov, and Frédéric Dollé, and Sandrine Bourgeois, and Jani Penttilä, and Eric Artiges, and Jean-Luc Martinot, and Christian Trichard
April 2008, Clinical pharmacology and therapeutics,
Claire Leroy, and Véronique Bragulat, and Ivan Berlin, and Marie-Claude Grégoire, and Michel Bottlaender, and Dimitri Roumenov, and Frédéric Dollé, and Sandrine Bourgeois, and Jani Penttilä, and Eric Artiges, and Jean-Luc Martinot, and Christian Trichard
January 1987, Science (New York, N.Y.),
Copied contents to your clipboard!